All Stories

J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, cofounder Patrick Hsu, Ph.D., told Fierce Biotech.

May 13, 2025 - 12:08
 0
J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus
Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, cofounder Patrick Hsu, Ph.D., told Fierce Biotech.
Read More

Tags:

Previous Article

Galapagos gets cold feet over plans to split up company

Next Article

STAT+: UnitedHealth swaps CEOs, suspends 2025 outlook

Related Posts

Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC

Qilu Pharmaceutical pays $38M upfront for greater China...

May 9, 2025  0

Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug

Dutch biotech Azafaros gains €132M series B to fund pha...

May 13, 2025  0

GSK posts phase 3 itch data as it closes in on FDA approval

GSK posts phase 3 itch data as it closes in on FDA appr...

May 8, 2025  0